The relationship between selenoprotein P and glucose metabolism in experimental studies

Nutrients

Volumn 5, Issue 6, 2013, Pages 1937-1948

  Mao, Jinyuan ^a   Teng, Weiping ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Gene expression; Glucose metabolism; Insulin; Selenium; Selenoprotein P

Indexed keywords

GLUCOSE; GLUCOSE 6 PHOSPHATASE; INSULIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); SELENIUM; SELENOPROTEIN P; TRACE ELEMENT;

DIABETOGENESIS; DIET; DNA MODIFICATION; EXPERIMENTAL STUDY; FEEDBACK SYSTEM; GLUCOSE METABOLISM; HUMAN; LIVER; MAMMAL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS; PROTEIN EXPRESSION; REVIEW; RISK FACTOR;

MAMMALIA;

EID: 84878451020     PISSN: 20726643     EISSN: None     Source Type: Journal    
DOI: 10.3390/nu5061937     Document Type: Review

References (57)

1. Schweizer, U.; Brauer, A.U.; Kohrle, J.; Nitsch, R.; Savaskan, N.E. Selenium and brain function: A poorly recognized liaison. Brain Res. Rev. 2004, 45, 164-178.
2. Boitani, C; Puglisi, R. Selenium, a key element in spermatogenesis and male fertility. Adv. Exp. Med. Biol. 2008, 636, 65-73.
3. Huang, Z.; Rose, A.H.; Hoffmann, P.R. The role of selenium in inflammation and immunity: From molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signal. 2012, 16, 705-743.
4. Schomburg, L. Selenium, selenoproteins and the thyroid gland: Interactions in health and disease. Nat. Rev. Endocrinol. 2012, 8, 160-171.
5. Muecke, R.; Schomburg, L.; Buentzel, J.; Kisters, K.; Micke, O. Selenium or no selenium-That is the question in tumor patients: A new controversy. Integr. Cancer Ther. 2010, 9, 136-141.
6. Ezaki, O. The insulin-like effects of selenate in rat adipocytes. J. Biol. Chem. 1990, 265, 1124-1128.
7. Roden, M.; Prskavec, M.; Furnsinn, C; Elmadfa, I.; Konig, J.; Schneider, B.; Wagner, O.; Waldhausl, W. Metabolic effect of sodium selenite: Insulin-like inhibition of glucagon-stimulated glycogenosis in the isolated perfused rat liver. Hepatology 1995, 22, 169-174.
8. Mueller, A.S.; Pallauf, J. Compendium of the antidiabetic effects of supranutritional selenate doses. In vivo and in vitro investigations with type ii diabetic db/db mice. J. Nutr. Biochem. 2006, 17, 548-560.
9. Czernichow, S.; Couthouis, A.; Bertrais, S.; Vergnaud, A.C.; Dauchet, L.; Galan, P.; Hercberg, S. Antioxidant supplementation does not affect fasting plasma glucose in the supplementation with antioxidant vitamins and minerals (su.Vi.Max) study in france: Association with dietary intake and plasma concentrations. Am. J. Clin. Nutr. 2006, 84, 395-399.
10. Bleys, J.; Navas-Acien, A.; Guallar, E. Serum selenium and diabetes in U.S. Adults. Diabetes Care 2007, 30, 829-834.
11. Laclaustra, M.; Navas-Acien, A.; Stranges, S.; Ordovas, J.M.; Guallar, E. Serum selenium concentrations and diabetes in U.S. Adults: National health and nutrition examination survey (nhanes) 2003-2004. Environ. Health Perspect. 2009, 117, 1409-1413.
12. Stranges, S.; Galletti, F.; Farinaro, E.; D'Elia, L.; Russo, O.; Iacone, R.; Capasso, C; Carginale, V.; de Luca, V.; Della Valle, E.; et al. Associations of selenium status with cardiometabolic risk factors: An 8-year follow-up analysis of the olivetti heart study. Atherosclerosis 2011, 217, 274-278.
13. Rajpathak, S.; Rimm, E.; Morris, J.S.; Hu, F. Toenail selenium and cardiovascular disease in men with diabetes. J. Am. College Nutr. 2005, 24, 250-256.
14. Akbaraly, T.N.; Arnaud, J.; Rayman, M.P.; Hininger-Favier, I.; Roussel, A.M.; Berr, C; Fontbonne, A. Plasma selenium and risk of dysglycemia in an elderly french population: Results from the prospective epidemiology of vascular ageing study. Nutr. Metabol. 2010, 7, 21; doi:10.1186/1743-7075-7-21.
15. Park, K.; Rimm, E.B.; Siscovick, D.S.; Spiegelman, D.; Manson, J.E.; Morris, J.S.; Hu, F.B.; Mozaffarian, D. Toenail selenium and incidence of type 2 diabetes in U.S. men and women. Diabetes Care 2012, 35, 1544-1551.
16. Rayman, M.P.; Blundell-Pound, G.; Pastor-Barriuso, R.; Guallar, E.; Steinbrenner, H.; Stranges, S. A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin. PLoS One 2012, 7, e45269.
17. Lippman, S.M.; Klein, E.A.; Goodman, P.J.; Lucia, M.S.; Thompson, I.M.; Ford, L.G.; Parnes, H.L.; Minasian, L.M.; Gaziano, J.M.; Hartline, J.A.; et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The selenium and vitamin e cancer prevention trial (select). JAMA 2009, 301, 39-51.
18. Klein, E.A.; Thompson, I.M., Jr.; Tangen, C.M.; Crowley, J.J.; Lucia, M.S.; Goodman, P.J.; Minasian, L.M.; Ford, L.G.; Parnes, H.L.; Gaziano, J.M.; et al. Vitamin E and the risk of prostate cancer: The selenium and vitamin e cancer prevention trial (select). JAMA 2011, 306, 1549-1556.
19. Stranges, S.; Marshall, J.R.; Natarajan, R.; Donahue, R.P.; Trevisan, M.; Combs, G.F.; Cappuccio, F.P.; Ceriello, A.; Reid, M.E. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: A randomized trial. Ann. Intern. Med. 2007, 147, 217-223.
20. Hill, K.E.; Wu, S.; Motley, A.K.; Stevenson, T.D.; Winfrey, V.P.; Capecchi, M.R.; Atkins, J.F.; Burk, R.F. Production of selenoprotein P (sepp1) by hepatocytes is central to selenium homeostasis. J. Biol. Chem. 2012, 287, 40414-40424.
21. Yang, S.J.; Hwang, S.Y.; Choi, H.Y.; Yoo, H.J.; Seo, J.A.; Kim, S.G.; Kim, N.H.; Baik, S.H.; Choi, D.S.; Choi, K.M. Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: Implications for insulin resistance, inflammation, and atherosclerosis. J. Clin. Endocrinol. Metabol. 2011, 96, E1325-E1329.
22. Misu, H.; Ishikura, K.; Kurita, S.; Takeshita, Y.; Ota, T.; Saito, Y.; Takahashi, K.; Kaneko, S.; Takamura, T. Inverse correlation between serum levels of selenoprotein P and adiponectin in patients with type 2 diabetes. PLoS One 2012, 7, e34952.
23. Saito, Y.; Sato, N.; Hirashima, M.; Takebe, G.; Nagasawa, S.; Takahashi, K. Domain structure of bi-functional selenoprotein P. Biochem. J. 2004, 381, 841-846.
24. Burk, R.F.; Hill, K.E.; Motley, A.K. Plasma selenium in specific and non-specific forms. BioFactors 2001, 14, 107-114.
25. Akesson, B.; Bellew, T.; Burk, R.F. Purification of selenoprotein P from human plasma. Biochim. Biophys. Acta 1994, 1204, 243-249.
26. Meplan, C.; Crosley, L.K.; Nicol, F.; Beckett, G.J.; Howie, A.F.; Hill, K.E.; Horgan, G.; Mathers, J.C.; Arthur, J.R.; Hesketh, J.E. Genetic polymorphisms in the human selenoprotein P gene determine the response of selenoprotein markers to selenium supplementation in a gender-specific manner (the selgen study). FASEB J. 2007, 21, 3063-3074.
27. Xia, Y.; Hill, K.E.; Byrne, D.W.; Xu, J.; Burk, R.F. Effectiveness of selenium supplements in a low-selenium area of china. Am. J. Clin. Nutr. 2005, 81, 829-834.
28. Combs, G.F., Jr.; Jackson, M.I.; Watts, J.C.; Johnson, L.K.; Zeng, H.; Idso, J.; Schomburg, L.; Hoeg, A.; Hoefig, C.S.; Chiang, E.C.; et al. Differential responses to selenomethionine supplementation by sex and genotype in healthy adults. Br. J. Nutr. 2012, 107, 1514-1525.
29. Hoffmann, P.R.; Hoge, S.C.; Li, P.A.; Hoffmann, F.W.; Hashimoto, A.C.; Berry, M.J. The selenoproteome exhibits widely varying, tissue-specific dependence on selenoprotein P for selenium supply. Nucl. Acids Res. 2007, 35, 3963-3973.
30. Kato, T.; Read, R.; Rozga, J.; Burk, R.F. Evidence for intestinal release of absorbed selenium in a form with high hepatic extraction. Am. J. Physiol. 1992, 262, G854-G858.
31. Schweizer, U.; Streckfuss, F.; Pelt, P.; Carlson, B.A.; Hatfield, D.L.; Kohrle, J.; Schomburg, L. Hepatically derived selenoprotein P is a key factor for kidney but not for brain selenium supply. Biochem. J. 2005, 386, 221-226.
32. Steinbrenner, H.; Hotze, A.L.; Speckmann, B.; Pinto, A.; Sies, H.; Schott, M.; Ehlers, M.; Scherbaum, W.A.; Schinner, S. Localization and regulation of pancreatic selenoprotein P. J. Mol. Endocrinol. 2013, 50, 31-42.
33. Lee, S.R.; Yon, J.M.; Baek, I.J.; Kim, M.R.; Park, C.G.; Lee, B.J.; Yun, Y.W.; Nam, S.Y. Spatiotemporal expression of the selenoprotein P gene in postimplantational mouse embryos. Int. J. Dev. Biol. 2008, 52, 1005-1011.
34. Niwa, H.; Harrison, L.C.; DeAizpurua, H.J.; Cram, D.S. Identification of pancreatic β cell-related genes by representational difference analysis. Endocrinology 1997, 138, 1419-1426.
35. Yang, X.; Jansson, P.A.; Nagaev, I.; Jack, M.M.; Carvalho, E.; Sunnerhagen, K.S.; Cam, M.C.; Cushman, S.W.; Smith, U. Evidence of impaired adipogenesis in insulin resistance. Biochem. Biophys. Res. Commun. 2004, 317, 1045-1051.
36. Zhang, Y.; Chen, X. Reducing selenoprotein P expression suppresses adipocyte differentiation as a result of increased preadipocyte inflammation. Am. J. Physiol. Endocrinol. Metab. 2011, 300, E77-E85.
37. Clark, L.C.; Combs, G.F., Jr.; Turnbull, B.W.; Slate, E.H.; Chalker, D.K.; Chow, J.; Davis, L.S.; Glover, R.A.; Graham, G.F.; Gross, E.G.; et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional prevention of cancer study group. JAMA 1996, 276, 1957-1963.
38. Duffield-Lillico, A.J.; Dalkin, B.L.; Reid, M.E.; Turnbull, B.W.; Slate, E.H.; Jacobs, E.T.; Marshall, J.R.; Clark, L.C. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: An analysis of the complete treatment period of the nutritional prevention of cancer trial. BJU Int. 2003, 91, 608-612.
39. Angstwurm, M.W.; Engelmann, L.; Zimmermann, T.; Lehmann, C.; Spes, C.H.; Abel, P.; Strauss, R.; Meier-Hellmann, A.; Insel, R.; Radke, J.; et al. Selenium in Intensive Care (SIC): Results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock. Crit. Care Med. 2007, 35, 118-126.
40. Campbell, S.C.; Aldibbiat, A.; Marriott, C.E.; Landy, C.; Ali, T.; Ferris, W.F.; Butler, C.S.; Shaw, J.A.; Macfarlane, W.M. Selenium stimulates pancreatic beta-cell gene expression and enhances islet function. FEBS Lett. 2008, 582, 2333-2337.
41. Speckmann, B.; Sies, H.; Steinbrenner, H. Attenuation of hepatic expression and secretion of selenoprotein P by metformin. Biochem. Biophys. Res. Commun. 2009, 387, 158-163.
42. Misu, H.; Takamura, T.; Takayama, H.; Hayashi, H.; Matsuzawa-Nagata, N.; Kurita, S.; Ishikura, K.; Ando, H.; Takeshita, Y.; Ota, T.; et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab. 2010, 12, 483-495.
43. Puigserver, P.; Rhee, J.; Donovan, J.; Walkey, C.J.; Yoon, J.C.; Oriente, F.; Kitamura, Y.; Altomonte, J.; Dong, H.; Accili, D.; et al. Insulin-regulated hepatic gluconeogenesis through foxo1-pgc-1α interaction. Nature 2003, 423, 550-555.
44. Speckmann, B.; Walter, P.L.; Alili, L.; Reinehr, R.; Sies, H.; Klotz, L.O.; Steinbrenner, H. Selenoprotein P expression is controlled through interaction of the coactivator pgc-1α with foxo1a and hepatocyte nuclear factor 4α transcription factors. Hepatology 2008, 48, 1998-2006.
45. Yoon, J.C.; Puigserver, P.; Chen, G.; Donovan, J.; Wu, Z.; Rhee, J.; Adelmant, G.; Stafford, J.; Kahn, C.R.; Granner, D.K.; et al. Control of hepatic gluconeogenesis through the transcriptional coactivator pgc-1. Nature 2001, 413, 131-138.
46. Rayman, M.P. Selenium and human health. Lancet 2012, 379, 1256-1268.
47. Burk, R.F.; Hill, K.E. Selenoprotein P-expression, functions, and roles in mammals. Biochim. Biophys. Acta 2009, 1790, 1441-1447.
48. Kurokawa, S.; Hill, K.E.; McDonald, W.H.; Burk, R.F. Long isoform mouse selenoprotein P (sepp1) supplies rat myoblast l8 cells with selenium via endocytosis mediated by heparin binding properties and apolipoprotein e receptor-2 (apoer2). J. Biol. Chem. 2012, 287, 28717-28726.
49. Olson, G.E.; Winfrey, V.P.; Nagdas, S.K.; Hill, K.E.; Burk, R.F. Apolipoprotein e receptor-2 (apoer2) mediates selenium uptake from selenoprotein P by the mouse testis. J. Biol. Chem. 2007, 282, 12290-12297.
50. Olson, G.E.; Winfrey, V.P.; Hill, K.E.; Burk, R.F. Megalin mediates selenoprotein P uptake by kidney proximal tubule epithelial cells. J. Biol. Chem. 2008, 283, 6854-6860.
51. Erranz, B.; Miquel, J.F.; Argraves, W.S.; Barth, J.L.; Pimentel, F.; Marzolo, M.P. Megalin and cubilin expression in gallbladder epithelium and regulation by bile acids. J. Lipid Res. 2004, 45, 2185-2198.
52. Lei, X.G.; Vatamaniuk, M.Z. Two tales of antioxidant enzymes on beta cells and diabetes. Antioxid. Redox Signal. 2011, 14, 489-503.
53. Walter, P.L.; Steinbrenner, H.; Barthel, A.; Klotz, L.O. Stimulation of selenoprotein P promoter activity in hepatoma cells by foxo1a transcription factor. Biochem. Biophys. Res. Commun. 2008, 365, 316-321.
54. Seale, L.A.; Hashimoto, A.C.; Kurokawa, S.; Gilman, C.L.; Seyedali, A.; Bellinger, F.P.; Raman, A.V.; Berry, M.J. Disruption of the selenocysteine lyase-mediated selenium recycling pathway leads to metabolic syndrome in mice. Mol. Cell. Biol. 2012, 32, 4141-4154.
55. Collins, R.; Johansson, A.L.; Karlberg, T.; Markova, N.; van den Berg, S.; Olesen, K.; Hammarstrom, M.; Flores, A.; Schuler, H.; Schiavone, L.H.; et al. Biochemical discrimination between selenium and sulfur 1: A single residue provides selenium specificity to human selenocysteine lyase. PLoS One 2012, 7, e30581.
56. Mihara, H.; Kurihara, T.; Watanabe, T.; Yoshimura, T.; Esaki, N. Cdna cloning, purification, and characterization of mouse liver selenocysteine lyase. Candidate for selenium delivery protein in selenoprotein synthesis. J. Biol. Chem. 2000, 275, 6195-6200.
57. Schomburg, L.; Schweizer, U. Hierarchical regulation of selenoprotein expression and sex-specific effects of selenium. Biochim. Biophys. Acta 2009, 1790, 1453-1462.